Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a Randomised, Double-Blind, Placebo-Controlled Trial

samir malhotra0 个研究点目标入组 102 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•?Age 18 years and above of either sex
•?Presence of New York Heart Association functional class II?IV of at least 4 weeks? duration
•?LVEF ≥ 50% in a nondilated LV (LV end-diastolic volume < 97 ml/m2 measured by echocardiography)
•?Echocardiographic evidence of LV diastolic dysfunction
•?Willing to give written informed consent

•?Clinically unstable as defined by any change in diuretic dose in the month prior to enrolment.
•?Significant valvular heart disease, pericardial disease, hypertrophic or restrictive cardiomyopathy
•?Unstable angina or MI within the past 4 weeks.
•?Alternative probable cause of the patient?s symptoms (e.g.significant pulmonary disease);
•?Any previous left ventricular ejection fraction below 40%
•?Other systemic disease limiting life expectancy to less than 3 years
•?Any contraindication to metoprolol use (heart rate less than 45 beats per minute, heart block greater than first-degree i.e. PR interval ≥ 0.24 second, systolic blood pressure <100 mm Hg, asthma)
•?Conditions associated with alteration in serum levels of procollagen type I e.g. alcoholic liver disease, metabolic bone disease, hyperthyroidism
•?Current participation (including prior 30 days) in any other therapeutic trial
•?Any condition that, in the opinion of the investigator, may prevent the participant from adhering to the trial protocol

发起方

samir malhotra